Cardiovascular Medicine and Haematology articles for South Korea

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 80

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
3 2.89
Engineering T Cells with Membrane-Anchored Nitric Oxide Scavengers for Anticancer Therapy 1.00
Combining Microfluidic Assessment with Encoded Hydrogel Microparticle-Based Immunoassay for Anti-Interleukin Drug Repurposing of Pulmonary Fibrosis Therapy 1.00
Tolerogenic Dendritic Cell- and M2 Macrophage Polarization-Inducible Hybrid Nanoparticles Alleviate Asthma in Mice 0.89
1 0.01
Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes 0.01
1 1.00
Wearable Multifunctional Epidermal Patch for Continuous and Reliable Blood Pressure Monitoring with Simultaneous Tracking of Physiological Health States 1.00
7 3.16
Single-cell Sequencing Unveils A Profibrotic Macrophage and Infiltrating Monocyte Niche in the Bronchoalveolar Lavage of Patients with Chronic Obstructive Pulmonary Disease 0.02
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.04
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial 0.14
Standalone Prognostication of Idiopathic Pulmonary Fibrosis Using Attention-Based Deep Learning 1.00
p300-Dependent Modulation in Regulatory T Cells Plays a Crucial Role in Allergic Asthma. 1.00
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study. 0.04
Impact of Sleep Apnea on Perivascular Diffusivity and Cognition: A 4-Year Prospective Cohort Study. 0.92
2 2.00
High-Flow Nasal Oxygenation in Infants Undergoing Tracheal Intubation: A Single-center Randomized Controlled Trial. 1.00
Cardiac Biomarkers and Risk Stratification in Liver Transplantation for Acute-on-Chronic Liver Failure: Refining Current Risk Models for Improved Prediction of Post-transplant Mortality. 1.00
1 1.00
Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial. 1.00
1 0.07
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study 0.07
1 1.00
Retrospective population-based cohort study on the risk of cardiovascular disease among oesophageal cancer survivors 1.00
4 2.94
Demographic and Physiological Differences Between Fibrotic and Nonfibrotic CT Subtypes of Sarcoidosis 0.11
Quantitative CT in Progressive Pulmonary Fibrosis: Clinical Utility and Meaningful Threshold Definition 1.00
Clinical Outcomes in Chronic Obstructive Pulmonary Disease Patients with Disease Stability: Data from the KOCOSS Cohort 1.00
Lung Cancer Risk in Preserved Ratio Impaired Spirometry and Airway Obstruction: A UK Biobank Study 0.83
5 2.04
Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis 0.09
Long-Term Outcomes of Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation: A Propensity Analysis. 1.00
New Algorithm for Estimating Left Ventricular Filling Pressure by Echocardiography. 0.07
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. 0.06
Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study. 0.82
1 1.00
Association Between Initial Left Ventricular Systolic Dysfunction and Clinical Outcome in Sepsis: A Multicenter Cohort Study. 1.00
6 4.00
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.04
Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study 0.95
Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION–STEMI trial 1.00
Dementia risk across blood pressure categories: a South Korean nationwide study 1.00
Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial 1.00
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.01
1 1.00
Peak oxygen consumption as a modifier of the obesity paradox in patients with obesity with heart failure with reduced ejection fraction 1.00
1 1.00
Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation 1.00
1 0.06
FAK activity exacerbates disturbed flow-mediated atherosclerosis via VEGFR2-CBL-NF-κB signaling 0.06
1 0.54
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models 0.54
3 0.15
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.05
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.04
Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. 0.07
1 0.71
Mechanisms underlying local Ca2+ signalling differences between right and left atrial myocytes at normal and increased frequencies 0.71
7 6.78
Mechanical versus bioprosthetic heart valves in patients on hemodialysis 1.00
Outcomes of Staged Repair Following Systemic-to-Pulmonary Artery Shunt in Pulmonary Atresia with Ventricular Septal Defect 1.00
Impacts of atrial fibrillation and surgical ablation on rheumatic and degenerative mitral surgeries 1.00
Outcomes of ischemic mitral regurgitation after coronary revascularization alone in patients with acute coronary syndrome 1.00
Comparison of bovine jugular vein conduits and polytetrafluoroethylene valved conduits for right ventricular outflow tract reconstruction 1.00
Risk of Reoperation Following Rheumatic Mitral Repair: Long-term Longitudinal Analysis 0.78
Impact of Preoperative CT Planning on Surgical Outcomes in Patients with Obstructive Hypertrophic Cardiomyopathy: A Prospective Cohort Study 1.00
9 2.25
Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis 0.29
Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk 0.03
Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023 0.26
Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease 0.50
Remnant Cholesterol as an Independent Cardiovascular Risk Factor in Young Adults : An Age-Stratified Cohort Study 1.00
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial 0.04
AHA PREVENT Equations and Cardiovascular Disease Risk in Diverse Health Care Populations 0.02
Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome An Optical Coherence Tomography Analysis 0.05
Long-Acting Factor XI Inhibition and Periprocedural Bleeding An Analysis From AZALEA-TIMI 71 0.05
2 1.03
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis 0.03
The REDD1–NF-κB–miRNAs–eNOS/SIRT1 axis mediates obesity-induced endothelial cell senescence and hypertension 1.00
1 0.02
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.02
1 0.08
Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials 0.08
2 0.56
Single-molecule dissection of CFTR folding defects and pharmacological rescue 0.50
Remote analysis and management of sweat biomarkers using a wearable microfluidic sticker in adult cystic fibrosis patients 0.06
3 2.13
Novel Dynamic Chest Radiography Technique for Assessing Pulmonary Regurgitation in Repaired Tetralogy of Fallot. 0.13
Radiologic Pattern of Fibrosis in Combined Pulmonary Fibrosis and Emphysema: Impact on Disease Trajectories and Prognostic Outcomes. 1.00
Longitudinal Tracking of Emphysema Holes at Noncontrast CT: Dynamic Patterns and Clinical Relationships. 1.00
1 0.02
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling 0.02
1 0.25
P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials 0.25
6 3.43
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial 1.00
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.03
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.05
Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial 1.00
Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION–STEMI): a multicentre, non-inferiority, open-label, randomised trial 1.00
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.35
6 4.07
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction 0.97
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease 1.00
Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years 1.00
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.06
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents 1.00
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis 0.04

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.